The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

G Cavaletti; DR Cornblath; ISJ (Ingemar) Merkies; TJ Postma; E Rossi; B Frigeni; P Alberti; J Bruna; R Velasco; AA Argyriou; HP Kalofonos; D Psimaras; D Ricard; A Pace; E Galie; C Briani; C Dalla Torre; CG Faber; RI Lalisang; W Boogerd; D (Dieta) Brandsma; S Koeppen; J Hense; DJ Storey; S Kerrigan; A Schenone; S Fabbri; MG Valsecchi

doi:10.1093/annonc/mds329

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

G Cavaletti, DR Cornblath, ISJ (Ingemar) Merkies, TJ Postma, E Rossi, B Frigeni, P Alberti, J Bruna, R Velasco, AA Argyriou, HP Kalofonos, D Psimaras, D Ricard, A Pace, E Galie, C Briani, C Dalla Torre, CG Faber, RI Lalisang, W BoogerdD (Dieta) Brandsma, S Koeppen, J Hense, DJ Storey, S Kerrigan, A Schenone, S Fabbri, MG Valsecchi

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

225 Citations (Scopus)

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.

Original language	Undefined/Unknown
Pages (from-to)	454-462
Number of pages	9
Journal	Annals of Oncology
Volume	24
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mds329
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mds329

Cite this

Cavaletti, G., Cornblath, DR., Merkies, ISJ., Postma, TJ., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, AA., Kalofonos, HP., Psimaras, D., Ricard, D., Pace, A., Galie, E., Briani, C., Dalla Torre, C., Faber, CG., Lalisang, RI., ... Valsecchi, MG. (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology, 24(2), 454-462. https://doi.org/10.1093/annonc/mds329

@article{945d8950251044f6a6287add52af2aed,

title = "The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings",

abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.",

author = "G Cavaletti and DR Cornblath and Merkies, {ISJ (Ingemar)} and TJ Postma and E Rossi and B Frigeni and P Alberti and J Bruna and R Velasco and AA Argyriou and HP Kalofonos and D Psimaras and D Ricard and A Pace and E Galie and C Briani and {Dalla Torre}, C and CG Faber and RI Lalisang and W Boogerd and Brandsma, {D (Dieta)} and S Koeppen and J Hense and DJ Storey and S Kerrigan and A Schenone and S Fabbri and MG Valsecchi",

year = "2013",

doi = "10.1093/annonc/mds329",

language = "Undefined/Unknown",

volume = "24",

pages = "454--462",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "2",

}

Cavaletti, G, Cornblath, DR, Merkies, ISJ, Postma, TJ, Rossi, E, Frigeni, B, Alberti, P, Bruna, J, Velasco, R, Argyriou, AA, Kalofonos, HP, Psimaras, D, Ricard, D, Pace, A, Galie, E, Briani, C, Dalla Torre, C, Faber, CG, Lalisang, RI, Boogerd, W, Brandsma, D, Koeppen, S, Hense, J, Storey, DJ, Kerrigan, S, Schenone, A, Fabbri, S & Valsecchi, MG 2013, 'The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings', Annals of Oncology, vol. 24, no. 2, pp. 454-462. https://doi.org/10.1093/annonc/mds329

TY - JOUR

T1 - The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

AU - Cavaletti, G

AU - Cornblath, DR

AU - Merkies, ISJ (Ingemar)

AU - Postma, TJ

AU - Rossi, E

AU - Frigeni, B

AU - Alberti, P

AU - Bruna, J

AU - Velasco, R

AU - Argyriou, AA

AU - Kalofonos, HP

AU - Psimaras, D

AU - Ricard, D

AU - Pace, A

AU - Galie, E

AU - Briani, C

AU - Dalla Torre, C

AU - Faber, CG

AU - Lalisang, RI

AU - Boogerd, W

AU - Brandsma, D (Dieta)

AU - Koeppen, S

AU - Hense, J

AU - Storey, DJ

AU - Kerrigan, S

AU - Schenone, A

AU - Fabbri, S

AU - Valsecchi, MG

PY - 2013

Y1 - 2013

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.

U2 - 10.1093/annonc/mds329

DO - 10.1093/annonc/mds329

M3 - Article

SN - 0923-7534

VL - 24

SP - 454

EP - 462

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -